Home › Sun Pharma and Merck & Co. Inc. Enter into Licensing Agreement for Tildrakizumab
 

Keywords :   


Sun Pharma and Merck & Co. Inc. Enter into Licensing Agreement for Tildrakizumab

2014-09-17 14:30:00| Merck.com - Corporate News

Dateline City: WHITEHOUSE STATION, N.J., and MUMBAI, India WHITEHOUSE STATION, N.J., and MUMBAI, India--(BUSINESS WIRE)--Merck & Co., Inc., (NYSE:MRK), known as MSD outside the United States and Canada, and Sun Pharmaceutical Industries Ltd. Language: English Contact: MerckMedia:Ian McConnell, 908- 423-3046Investor:Justin Holko, 908-423-5088orSun PharmaMedia:Frederick Castro, +91-22-66455964Investor:Nimish Desai, +91-22-66455717 Ticker Slug: Ticker: MRK Exchange: NYSE Ticker: 524715 Exchange: MUMBAI read more

Tags: for enter agreement sun

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.11Registration Now Open for RadTech 2025
05.11Atlantic Tropical Weather Outlook
05.11Eastern North Pacific Tropical Weather Outlook
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Public Advisory Number 7A
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Vodafone-Three merger could get green light, watchdog says
05.11Altice USA residential video RGUs down 77,000 in 3Q 2024
More »